Toxicological Evaluation of D-Allulose Produced by a Novel One-Step Fermentation Process Using Genetic Methods

If you buy sweeteners for a living, you read safety studies with a skeptical eye. Many leave more questions than answers. This one is different. Researchers evaluated D-allulose produced through a novel one-step fermentation process using genetically engineered Escherichia coli AS10. They ran a 90-day oral toxicity study in rats. The no observed adverse effect level came in at 8,000 mg per kg body weight per day. That number gives formulators and buyers a concrete safety reference.

Why formulators should care

D-allulose has been on formulation benches for years. The missing piece was not application data; it was production-scale toxicology. The paper confirms that D-allulose from this one-step fermentation route behaves like sucrose in three practical areas: solubility, texture, and thermal stability. It also confirms a high safety threshold in an accepted animal model.

That combination matters. A sweetener that dissolves poorly or breaks down under heat is useless. One that needs a complicated supply chain is risky. Here, the production process and the safety profile point in the same direction.

What the study did

The team took D-allulose made by the engineered AS10 strain and fed it to rats daily for 90 days. They looked for signs of toxicity across multiple dose levels. The highest dose with no adverse effects became the NOAEL.

That value was 8,000 mg/kg body weight/day. For a 70 kg adult, this translates to about 560 g per day. Real-world intakes sit far below that. The margin is wide.

Key findings

The table below compares the functional properties of this D-allulose to sucrose, based on the study.

Property	D-Allulose (this study)	Sucrose
Solubility	Similar to sucrose	Reference standard
Texture	Similar to sucrose	Reference standard
Thermal stability	Similar to sucrose	Reference standard
90-day oral toxicity benchmark	NOAEL 8,000 mg/kg bw/day	Not assessed in this study

The NOAEL is the key regulatory milestone. The functional data matters for your production line. Solubility affects syrup handling. Texture affects mouthfeel. Thermal stability affects whether you can use the sweetener in baked or heated systems.

What this means for manufacturers

Ingredient buyers should treat this as a baseline, not an endpoint. Ask suppliers whether they use the same one-step fermentation process and the AS10 strain. Ask for their batch purity data. Confirm that their product matches the material tested in this study.

Formulators should also request the full study protocol. A 90-day NOAEL is strong evidence, but your application depends on more than toxicology. You need to know how the sweetener behaves in your specific system. The paper gives you a starting point.

FAQ

Does the NOAEL mean this allulose is safe for humans?

It means the tested ingredient caused no adverse effects at 8,000 mg/kg body weight/day in rats over 90 days. Regulators apply safety factors to animal data when setting human guidelines. The number here is high enough to support food use.

Should I worry about the genetically engineered E. coli strain?

The study assessed the final D-allulose, not the live microorganism. The AS10 strain serves as the production organism. You should still ask suppliers about purification and removal of process impurities. The toxicology study used finished ingredient, not the fermentation broth.

Can this allulose replace sucrose in my formula right away?

Not without testing. The study showed similar solubility, texture, and thermal stability. It did not measure sweetness or specific product performance. Run pilot trials before full production.

The bigger picture

The evidence gap for D-allulose just got narrower. A one-step fermentation process plus a 90-day toxicity study gives you a practical way to evaluate supply offers. Use this paper as a benchmark. The next step is your own trial.